Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSQT3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,673
Award facts
- Contract value 100% obligated
- $25,673.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $25,673.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The contract, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries no set-aside designation, indicating the vendor competed in an unrestricted procurement. DMS Pharmaceutical Group is registered as a critical supplier within the federal pharmaceutical supply chain and maintains substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The PPV-G GEN V program is part of a broader $30.3 billion acquisition strategy designed to establish regional prime vendor contractors that supply pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. EXPAREL is a specialty surgical anesthetic product that aligns with the comprehensive pharmaceutical portfolio DMS Pharmaceutical Group supplies under the prime vendor agreement.
Quick answers
Who was awarded contract SPE2DR26FSQT3?
SPE2DR26FSQT3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FSQT3 worth?
The government has obligated $25,673 on SPE2DR26FSQT3.
Is contract SPE2DR26FSQT3 an order under another contract?
Yes. SPE2DR26FSQT3 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQT3 competed?
The extent of competition for SPE2DR26FSQT3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award